Julie R. Park
Julie Park led the COG trial that made tandem transplant standard for high-risk neuroblastoma.
Pediatric oncologist and study chair of COG ANBL0532, which showed tandem autologous transplant improves event-free survival in high-risk neuroblastoma, and a leader in anti-GD2 immunotherapy studies.
Pages like this
not linked directly; found by shared links- PersonAlice L. Yu
Shares COG ANBL0032, Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Children's Oncology Group (COG).
- InstitutionUniversity of Wisconsin Carbone Cancer Center
Shares Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Children's Oncology Group (COG), Neuroblastoma (paediatric).
- PairingAnti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)
Shares Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Neuroblastoma (paediatric).
- TechnologyTandem autologous transplant
Shares COG ANBL0532, Neuroblastoma (paediatric).
- InstitutionUC San Diego Moores Cancer Center
Shares Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Children's Oncology Group (COG), Neuroblastoma (paediatric).
- PairingCaution: IL-2 added to anti-GD2 therapy
Shares Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
- CompanyY-mAbs Therapeutics
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric).
- InstitutionTexas Children's Cancer and Hematology Center
Shares GD2 (disialoganglioside), Children's Oncology Group (COG), Neuroblastoma (paediatric).